文献速递妇科

腹腔热灌注化疗(HIPEC)在卵巢癌中的作用

The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2025-08-04

本系统综述按PRISMA指南纳入7项III期随机对照试验,共1252例卵巢癌患者,其中630例接受手术加HIPEC、622例仅手术。综述评估HIPEC在初次减瘤、间隔减瘤及二次减瘤中的角色,聚焦无进展生存与总生存,并讨论患者选择、化疗方案、技术操作、围手术期护理、潜在副作用、成本效益及与靶向治疗联合等新兴方向。

要点

  • 共纳入7项III期随机对照试验,1252例卵巢癌患者中630例接受手术加HIPEC、622例仅手术。
  • 综述评估HIPEC在初次减瘤、间隔减瘤和二次减瘤中的作用,重点为无进展生存与总生存。
  • HIPEC是有前景的治疗进展,但需进一步高质量研究以完善其使用并评估其在疾病更早阶段的作用。

核心结论

  • HIPEC是有前景的治疗进展,但需进一步高质量研究以完善其使用并评估其在疾病更早阶段的作用。
  • 本综述旨在为临床决策提供信息并支持卵巢癌不断演变的管理中的未来研究。

研究设计与样本

  • 按PRISMA指南进行的系统综述,纳入测试HIPEC在卵巢癌中作用的III期随机对照试验。
  • 共纳入7项随机对照试验,检查1252例卵巢癌患者的数据:630例接受手术加HIPEC,622例仅接受手术。

主要发现

  • 综述评估HIPEC在多种临床场景中的作用,包括初次减瘤手术、间隔减瘤手术和二次减瘤。
  • 总结关键临床试验证据,聚焦其对无进展生存和总生存的影响。
  • 检查患者选择、化疗方案、技术操作和围手术期护理等重要因素。
  • 讨论潜在副作用,包括肾毒性、胃肠道损伤和恢复延迟。
  • 评估成本效益及HIPEC纳入多学科治疗计划,并探索HIPEC与靶向治疗联合及个体化治疗策略等新兴方法。

局限性

  • 原文指出需进一步高质量研究以完善HIPEC的使用并评估其在疾病更早阶段的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly recognized as an effective addition to cytoreductive surgery in advanced ovarian cancer, particularly in patients who respond to platinum-based chemotherapy. METHODS: A systematic review of phase III randomized controlled trials testing the role of HIPEC in ovarian cancer was performed, according to the PRISMA guidelines. RESULTS: Seven randomized controlled trials were included. Data of 1252 patients with ovarian cancer were examined: 630 and 622 having surgery plus HIPEC and surgery alone, respectively. This review critically evaluates the role of HIPEC in various clinical scenarios, including primary and interval debulking surgery and secondary cytoreduction. Evidence from key clinical trials is summarized, focusing on its effects on progression-free and overall survival. Important factors such as patient selection, chemotherapy regimens, technical procedures, and perioperative care are examined. Potential side effects (including renal toxicity, gastrointestinal injury, and delayed recovery) are discussed. The review also assesses cost-effectiveness and integration of HIPEC into multidisciplinary treatment plans. Emerging approaches, such as combining HIPEC with targeted therapies and personalized treatment strategies, are explored. CONCLUSIONS: While HIPEC offers a promising therapeutic advance, further high-quality studies are needed to refine its use and assess its role in earlier stages of disease. This review aims to inform clinical decisions and support future research in the evolving management of ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bogani G, Fagotti A, Chiantera V, et al. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Gynecol Oncol. 2025. PMID: 40763418. doi:10.1016/j.ygyno.2025.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。